A 48-year-old Indian man with EGFR-mutant (exon 19 deletion) advanced non-small-cell lung cancer (NSCLC) is started on gefitinib, a first-generation EGFR tyrosine kinase inhibitor (TKI). After 14 months of excellent response, he develops progressive dyspnea and imaging shows new pulmonary nodules despite continued gefitinib therapy. Repeat molecular testing reveals an acquired T790M mutation in EGFR. Which targeted agent is most appropriate for this acquired resistance?

Explanation

## EGFR Mutation-Driven NSCLC and Acquired Resistance ### Clinical Scenario Breakdown The patient has: - Initial EGFR exon 19 deletion (sensitizing mutation) → excellent response to gefitinib - Progression after 14 months (median progression-free survival ~10–13 months with first-gen TKI) - Acquired T790M mutation on repeat testing **Key Point:** T790M is the most common mechanism of acquired resistance to first- and second-generation EGFR TKIs, occurring in ~50–60% of cases with acquired resistance. ### Mechanism of T790M Resistance ```mermaid flowchart TD A[First-generation EGFR TKI<br/>gefitinib, erlotinib]:::action --> B[Selective pressure on EGFR mutant cells]:::outcome B --> C[Subclonal T790M mutation emerges]:::outcome C --> D{T790M mechanism}:::decision D -->|Steric hindrance| E[Prevents TKI binding to kinase domain]:::outcome D -->|Increased ATP affinity| F[Outcompetes ATP-competitive inhibitor]:::outcome E --> G[Resistance to 1st & 2nd gen TKIs]:::urgent F --> G G --> H[Third-generation TKI needed:<br/>osimertinib, aftinib]:::action ``` ### Osimertinib: The Gold Standard for T790M | Feature | First-Gen TKI | Second-Gen TKI | Third-Gen TKI (Osimertinib) | |---------|---|---|---| | **Target** | EGFR exon 19/21 | EGFR + HER2 | EGFR + T790M (selective) | | **T790M Activity** | No | Minimal | Yes (irreversible) | | **Mechanism** | Reversible | Irreversible | Irreversible + covalent | | **Dose** | 250 mg daily | 1150 mg daily | 80 mg daily | | **Median PFS** | 10–13 mo | 12–15 mo | 10–12 mo (T790M+) | | **CNS penetration** | Poor | Moderate | Excellent | **High-Yield:** Osimertinib is specifically designed to: 1. Bind irreversibly to the T790M-mutated kinase domain 2. Spare wild-type EGFR (lower toxicity) 3. Achieve excellent CNS penetration (important for brain metastases) ### Clinical Evidence - **AURA3 trial:** Osimertinib vs. platinum-pemetrexed in T790M+ NSCLC after TKI progression → median PFS 10.1 vs. 4.4 months; OS benefit also demonstrated. - **Dosing:** 80 mg daily (lower than first-gen TKIs due to high potency) **Clinical Pearl:** Osimertinib can be used upfront (without prior TKI) in EGFR-mutant NSCLC as first-line therapy, but in this case it is indicated for acquired T790M resistance. ### Why Other Options Are Incorrect **Option 0 (Erlotinib):** Another first-generation EGFR TKI. T790M confers cross-resistance to all first- and second-generation TKIs due to the same steric mechanism. Switching to erlotinib will not overcome T790M resistance. **Option 2 (Bevacizumab):** Anti-VEGF monoclonal antibody. While bevacizumab can be added to chemotherapy in EGFR-mutant NSCLC, it does not address the underlying EGFR T790M mutation and is not the targeted solution for this specific resistance mechanism. **Option 3 (Crizotinib):** ALK inhibitor. This patient has EGFR-mutant, not ALK-rearranged NSCLC. Crizotinib is irrelevant and would not target the T790M mutation. ### Acquired Resistance Beyond T790M If osimertinib fails (median PFS ~10–12 months), further resistance mechanisms include: - C797S mutation (prevents osimertinib binding) - MET amplification - HER2 amplification - Histologic transformation to small-cell lung cancer These may require combination therapy or clinical trial enrollment. [cite:Harrison 21e Ch 397; KD Tripathi 8e Ch 62]